Discontinued neuropathic pain therapy between 2009–2015

References

• van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654–662.
   PubMed Web of Science ®Google Scholar

**Systematic review of epidemiological studies of neuropathic pain in the general population with twenty-one articles identified, underwent quality assessment and data extraction with highlighting the importance of a standardized approach for identifying neuropathic pain

• Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281–289.
   PubMed Web of Science ®Google Scholar

*Study of the prevalence and distribution of pain of neuropathic origin in the general population, using a previously validated and reliable data collection instrument-Leeds Assessment of Neuropathic Symptoms and Signs score (S-LANSS) as a mailed postal survey

• BioLineRx. BioLineRx announces publication of EAGLE study results demonstrating BL-1020’s efficacy in improving cognitive function in schizophrenia patients [Internet]; 2012. [cited 2015 Jul 30]. Available from: http://www.biolinerx.com/default.asp?pageid=16&itemid=132.
   Google Scholar
• BioLineRx. BioLineRx presents pre-clinical data demonstrating that BL-1021 is safe and effective… [Internet]; 2008. [cited 2015 Jul 30]. Available from: http://www.reuters.com/article/2008/01/28/idUS108105+28-Jan-2008+BW20080128.
   Google Scholar
• Nisemblat Y, Savitsky K, Klapper L, et al. BL-1021: new chemical entity for the treatment of neuropathic pain. 13th World Congress on Pain; 2010 Aug 29–Sep 2; Montreal.
   Google Scholar
• BioLineRx. BioLineRx announces positive preliminary results from phase I clinical trial of BL-1021 for neuropathic pain [Internet]; 2011. [cited 2015 Jul 30]. Available from: http://www.biolinerx.com/default.asp?pageid=16&itemid=87.
   Google Scholar
• BioLineRx. A study intended to evaluate safety, tolerability and pharmacokinetics (PK) parameters of BL-1021 [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01121380?term=BL-1021&rank=1.
   Google Scholar
• Ltd B. BioLineRx announces results from interim analysis of phase II/III CLARITY trial of BL-1020 for schizophrenia [Internet]; 2013. [cited 2015 Jul 30]. Available from: http://www.biolinerx.com/default.asp?pageid=16&itemid=180.
   Google Scholar
• Smith SM, Uslaner JM, Hutson PH. The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors. Open Med Chem J. 2010;4:3–9.
   PubMedGoogle Scholar
• Sunovion A. Phase 1, open-label, single-photon emission computed tomography (SPECT) study to evaluate serotonin and dopamine transporter occupancy after multiple dose administration of SEP-228432 to achieve steady state in healthy subjects [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT01531972?term=SEP-228432&rank=1.
   Google Scholar
• News RDFD. NSD 644 GlaxoSmithKline discontinued NeuroSearch discontinued NeuroSearch phase change I, Denmark(depression) [Internet]; 2009. [cited 2015 Jul 30]. Available from: http://business.highbeam.com/436989/article-1G1-193894086/nsd-644-glaxosmithkline-discontinued-neurosearch-discontinued.
   Google Scholar
• Guagnini F, Ferazzini M, Grasso M, et al. Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa. J Transl Med. 2012;10:59.
   PubMed Web of Science ®Google Scholar
• Grisk OST, Reimer N, Zimmermann U, et al. The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012;30(5):980–989.
   PubMed Web of Science ®Google Scholar
• Pharma MGI. Company presentation annual report [Internet]; 2006. [cited 2015 Jul 30]. Available from: http://library.corporate-ir.net/library/73/738/73842/items/240642/MGI06AR.pdf.
   Google Scholar
• Peng XQ, Li J, Gardner EL, et al. Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. Eur J Pharmacol. 2010;627:1–3.
   PubMed Web of Science ®Google Scholar
• Adinsight [Internet]. 2010. [cited 2015 Jul 30]. Available from: http://adisinsight.springer.com/drugs/800031069.
   Google Scholar
• AstraZeneca. Study to investigate the analgesic efficacy of a single dose of AZD1940 [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00659490?term=NCT00659490&rank=1.
   Google Scholar
• Neomed. Product pipeline [Internet]; 2015. [cited 2015 Jul 30]. Available from: http://neomed.ca/en/portfolio/.
   Google Scholar
• Mattia CCF. Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. Idrugs. 2007;10(9):636–644.
   PubMed Web of Science ®Google Scholar
• Vernalis. Study of the safety, tolerability and efficacy of V3381 in patients with diabetic peripheral neuropathic pain [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00794430?term=vernalis&rank=6.
   Google Scholar
• Vernalis. Phase II open-label pilot study of V3381 in chronic cough [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01401673?term=vernalis&rank=5.
   Google Scholar
• Sanofi. Efficacy and safety study of ataciguat versus placebo in patients with neuropathic pain (SERENEATI) [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00799656?term=ataciguat&rank=2.
   Google Scholar
• Sanofi. Efficacy and safety of HMR1766 in patients with fontaine stage II peripheral arterial disease (ACCELA) [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00443287?term=NCT00443287&rank=1.
   Google Scholar
• Miller JD. Safety of ataciguat in patients with moderate calcific aortic valve stenosis [Internet]; 2015. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02049203?term=NCT02049203&rank=1.
   Google Scholar
• Clinic M. A study evaluating the effects of ataciguat (HMR1766) on aortic valve calcification (CAVS) [Internet]; 2015. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02481258?term=NCT02481258&rank=1.
   Google Scholar
• Zalicus. Phase 2 efficacy trial of Z160 in lumbosacral radiculopathy [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01655849?term=Z-160&rank=1.
   Google Scholar
• Zalicus. Efficacy and safety study of Z160 in subjects with postherpetic neuralgia (PHN) [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01757873?term=Z-160&rank=2.
   Google Scholar
• Biovitrum SO. Tolerability of novel A2A agonist in treatment of diabetic neuropathic pain [Internet]; 2007. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00452777?term=biovitrum&rank=2.
   Google Scholar
• Pharmaceuticals C. Safety and efficacy study of ADL5859 in participants with neuropathic pain associated with diabetic peripheral neuropathy [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00603265?term=ADL-5859&rank=4.
   Google Scholar
• Pharmaceuticals C. Study evaluating the analgesic efficacy and safety of ADL5859 in participants with rheumatoid arthritis [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00626275?term=ADL-5859&rank=1.
   Google Scholar
• Pharmaceuticals C. Analgesic efficacy and safety of ADL5859 in subjects with acute dental pain after third molar extraction [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00993863?term=ADL-5859&rank=2.
   Google Scholar
• Mony LKJ, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol. 2009;157(8):1301–1317.
   PubMed Web of Science ®Google Scholar
• Laboratories F. Study of the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00838799?term=RGH896&rank=1.
   Google Scholar
• Pfizer. PH-797804 LPS study in healthy volunteers [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02084485?term=NCT02084485&rank=1.
   Google Scholar
• Pfizer. A study to investigate the effect of PH-797804 on QTc interval [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01862887?term=NCT01862887&rank=1.
   Google Scholar
• Pfizer. A study to investigate the effect of erythromycin on the pharmacokinetics of PH-797804 [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01589614?term=NCT01589614&rank=1.
   Google Scholar
• Pfizer. A study to investigate the effect of food on the pharmacokinetics of PH-797804 [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01479647?term=NCT01479647&rank=1.
   Google Scholar
• Pfizer. Study to evaluate the efficacy and safety of PH-797804 for 12 weeks in adults with moderate to severe chronic obstructive pulmonary disease (COPD) on a background of tiotropium bromide [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01543919?term=A6631033&rank=1.
   Google Scholar
• Pfizer. Study to evaluate the efficacy and safety of PH-797804 for 12 Weeks in adults with moderate to severe chronic obstructive pulmonary disease (COPD) taking salmeterol xinafoate/fluticasone propionate combination [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01321463?term=A6631029&rank=1.
   Google Scholar
• Pfizer. Clinical trial to examine the pain relief of PH-797804 alone or with naproxen in subjects with osteoarthritis of the knee [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01102660?term=A6631026&rank=1.
   Google Scholar
• Pfizer. PH-797804 versus placebo for the treatment of neuropathic pain associated with post-herpetic neuralgia [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00614705?term=NCT00614705&rank=1.
   Google Scholar
• Pfizer. Study to evaluate the efficacy and safety of PH-797804 for 12 weeks in adults with moderate to severe chronic obstructive pulmonary disease (COPD) on a background of tiotropium bromide [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01543919?term=tiotropium+bromide+PH-797804&rank=1.
   Google Scholar
• Pfizer. A phase II, study to evaluate the efficacy and safety of PH-797804 in adults with moderate to severe chronic obstructive pulmonary disease (COPD) [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00559910?term=NCT00559910&rank=1.
   Google Scholar
• Pfizer. Clinical trial to examine the pain relief of PH-797804 alone or with naproxen in subjects with osteoarthritis of the knee [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01102660?term=NCT01102660&rank=1.
   Google Scholar
• Pfizer. PH-797804 versus placebo for the treatment of neuropathic pain associated with post-herpetic neuralgia [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00614705?term=NCT00614705&rank=1.
   Google Scholar
• Swedberg MDRP. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J Pharmacol Exp Ther. 2014;350(2):212–222.
   PubMed Web of Science ®Google Scholar
• Rohof WO, Lei A, Hirsch DP, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther. 2012;35(10):1231–1242.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01145755.
   Google Scholar
• AstraZeneca, editor. Efficacy and safety of the mGluR5 antagonist AZD2066 in painful diabetes neuropathy (PDN): results of a phase IIa randomised, double-blind, placebo-controlled study [Internet]. 4th World Congress on Pain, 2012 Aug 27–31. [cited 2015 Jul 30]. Available from: http://delta.larvol.com/Products/b352865a0eb941e1a6b7ddaba48cbc0d/AZD2066/8/3185ce22bc0b40089143fc6166e43534/Efficacy-and-safety-of-the-mGluR5-antagonist-AZD2066-in-painful-diabetes-neuropathy-PDN-results-of-a-phase-IIa-randomised-doubleblind-placebocontrolled-study/.
   Google Scholar
• AstraZeneca. To investigate the safety, tolerability and pharmacokinetics of AZD2516 after multiple dosing in healthy volunteers [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01148095.
   Google Scholar
• AstraZeneca. An open label positron emission tomography (PET) study to determine central mGluR5 receptor occupancy of AZD2516 [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00892944?term=AZD2516&rank=1.
   Google Scholar
• AstraZeneca. Study to assess safety, tolerability and pharmacokinetics after single dose of AZD2516 to Japanese healthy subjects [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00972049?term=AZD2516&rank=2.
   Google Scholar
• AstraZeneca. Study to assess safety, tolerability and pharmacokinetics after single doses of AZD2516 to healthy volunteers [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00754715?term=AZD2516&rank=3.
   Google Scholar
• AstraZeneca. Study to investigate the pharmacodynamic effect of a single dose of AZD2516 in healthy male subjects [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01154634?term=AZD2516&rank=5.
   Google Scholar
• Astellas. R&D Pipeline Q2 [Internet]; 2014. [cited 2015 Jul 30]. Available from: http://www.astellas.com/en/ir/library/pdf/2q2015_rd_en.pdf.
   Google Scholar
• Astellas. A study to assess the safety, tolerability, and effects in and on the body of healthy young and elderly male and female subjects of ascending multiple oral doses of ASP3652 [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02243657?term=NCT02243657&rank=1.
   Google Scholar
• Astellas. A study to assess the pharmacokinetics, metabolism and excretion routes of ASP3652 in man, after administration of 14C radio labeled ASP3652 [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02046798?term=NCT02046798&rank=1.
   Google Scholar
• Astellas. A study to investigate the appearance and disappearance of ASP3652 in blood and spinal fluid in healthy male subjects [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02034734?term=NCT02034734&rank=1.
   Google Scholar
• Astellas. A study to assess the effect of race on how a single dose of ASP3652 is taken up, metabolized and distributed through the bodies of young, healthy male and female subjects, and its safety and tolerability [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01958047?term=NCT01958047&rank=1.
   Google Scholar
• Astellas. A study to assess the safety, tolerability and effects of single ascending doses of ASP3652 in healthy subjects [Internet]; 2013. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01815684?term=NCT01815684&rank=1.
   Google Scholar
• Astellas. A study to assess the effect of multiple doses of gemfribozil on a single dose of ASP3652, and to assess the effects of multiple doses of ASP3652 on a single dose of repaglinide in the body of healthy subjects [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01797198?term=NCT01797198&rank=1.
   Google Scholar
• R&D Pipeline [press release] [Internet]. 2013. [cited 2015 Jul 30]. Available from: http://www.astellas.com/en/ir/library/pdf/3q2013_rd_en.pdf.
   Google Scholar
• Astellas. R&D Pipeline Q1 [Internet]; 2014. [cited 2015 Jul 30]. Available from: http://www.astellas.com/en/ir/library/pdf/1q2015_rd_en.pdf.
   Google Scholar
• Astellas. R&D Pipeline Q2 [Internet]; 2011. [cited 2015 Jul 30]. Available from: http://www.astellas.com/en/ir/library/pdf/2011_rd_en.pdf.
   Google Scholar
• Astellas. A clinical study to investigate the efficacy, safety and pharmacokinetics of ASP3652 in patients with chronic abacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) (AZURE) [Internet]; 2011. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01391338?term=ASP-3652&rank=8.
   Google Scholar
• Astellas. A randomized study comparing placebo and ASP3652 in the treatment of women with bladder pain syndrome/interstitial cystitis (BPS/IC) (AMARANTH) [Internet]; 2014. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01613586?term=ASP-3652&rank=7.
   Google Scholar
• AbbVie. A safety and efficacy study in subjects with diabetic neuropathic pain; 2007. Available from: https://clinicaltrials.gov/ct2/show/NCT00548925?term=NCT00548925&rank=1.
   Google Scholar
• AbbVie. Safety and efficacy study in subjects with diabetic neuropathic pain [Internet]; 2007. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00507936?term=NCT00507936&rank=1.
   Google Scholar
• Fleisher CMJ, Mc Gough J. Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014;23(8):1157–1163.
   PubMed Web of Science ®Google Scholar
• AbbVie. A dose-ranging study of the efficacy of ABT-894 in adults with attention-deficit/hyperactivity disorder (ADHD) [Internet]; 2007. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00429091?term=NCT00429091&rank=1.
   Google Scholar
• AstraZeneca. Study to investigate safety, tolerability and pharmacokinetics of AZD2423 multiple doses in healthy Japanese volunteers [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01233830?term=NCT01233830&rank=1.
   Google Scholar
• AstraZeneca. Study evaluating absorption, distribution, metabolism and excretion (ADME) of single dose [14C] AZD2423 in volunteers [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01223014?term=NCT01223014&rank=1.
   Google Scholar
• AstraZeneca. Study to investigate safety, tolerability and pharmacokinetics of AZD2423 multiple doses in healthy volunteers [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00977626?term=NCT00977626&rank=1.
   Google Scholar
• AstraZeneca. AZD2423 single ascending dose study in healthy Japanese subjects (JSAD) [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00970775?term=NCT00970775&rank=1.
   Google Scholar
• AstraZeneca. Study to investigate safety, tolerability and pharmacokinetics of AZD2423 in healthy volunteers (SAD) [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00940212?term=NCT00940212&rank=1.
   Google Scholar
• AstraZeneca. Investigation of the effect of oral treatment with 100 mg AZD2423 in subjects with mild chronic obstructive pulmonary disease (COPD) [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01153321?term=NCT01153321&rank=1.
   Google Scholar
• AstraZeneca. AZD2423 safety and tolerability study in patients with moderate and severe chronic obstructive pulmonary disease(COPD) [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01215279?term=NCT01215279&rank=1.
   Google Scholar
• AstraZeneca. A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgia [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01200524?term=NCT01200524&rank=1.
   Google Scholar
• AstraZeneca. A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with painful diabetic polyneuropathy [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01201317?term=NCT01201317&rank=1.
   Google Scholar
• Kalliomäki J, Attal N, Jonzon B, et al. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain. 2013;154(5):761–767.
   PubMed Web of Science ®Google Scholar
• Gierse J, Nickols M, Leahy K, et al. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur J Pharmacol. 2008;588(1):93–98.
   PubMed Web of Science ®Google Scholar
• Obukowicz M, Talley J. Chromene COX-2 inhibitor project [Internet]; 2008. [cited 2015 Jul 30]. Available from: http://english.gibh.cas.cn/drug/ec/cc/.
   Google Scholar
• Pfizer. From R&D Focus Drug News [Internet]. 2008 Jan 21. [cited 2015 Jul 30]. Available from: http://business.highbeam.com/436989/article-1G1-173550860/sc-75416-pfizer-discontinued.
   Google Scholar
• Gay RD, Clarke AW, Elgundi Z, et al. Anti-TNFα domain antibody construct CEP-37247: full antibody functionality at half the size. MAbs. 2010;2(6):625–638.
   PubMed Web of Science ®Google Scholar
• Arana Therapeutics AAHX Trial for Lead Compound [press release] [Internet]. 2008. [cited 2015 Jul 30]. Available from: https://yvepiw.wordpress.com/2012/08/31/arana-announces-phase-ii-trials-for-lead-compound-art621/
   Google Scholar
• Halloran KJ, Russell BW, Shipplett RA. Patent EP1562900 A1: polymorphs of bicifadine hydrochloride [Internet]; 2006. [cited 2015 Jul 30]. Available from: http://www.google.com.ar/patents/EP1562900A1?cl=en.
   Google Scholar
• Nicholson KL, Balster RL, Golembiowska K, et al. Preclinical evaluation of the abuse potential of the analgesic bicifadine. J Pharmacol Exp Ther. 2009;330(1):236–248.
   Google Scholar
• Biopharmaceuticals X. A 52-week study of bicifadine in patients with chronic neuropathic pain associated with diabetic peripheral neuropathy [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00597649?term=bicifadine&rank=4.
   Google Scholar
• Pharmaceuticals D. Efficacy and safety of bicifadine in the treatment of chronic low back pain [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00295711?term=bicifadine&rank=1.
   Google Scholar
• Arnold LM, Chatamra K, Hirsch I, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2010;32(9):1618–1632.
   PubMed Web of Science ®Google Scholar
• Pfizer. A trial assessing the effectiveness and safety of [S,S]-reboxetine in patients with fibromyalgia [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00357825?term=NCT00357825&rank=1.
   Google Scholar
• Pfizer. A trial of [S,S]-reboxetine in patients with chronic painful diabetic peripheral neuropathy [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00625833?term=NCT00625833&rank=1.
   Google Scholar
• Pfizer. [S,S]-reboxetine long term safety study in chronic painful diabetic peripheral neuropathy [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00348894?term=NCT00348894&rank=1.
   Google Scholar
• Pfizer. [S,S]-reboxetine add-on trial [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00334685?term=NCT00334685&rank=1.
   Google Scholar
• Pfizer. [S,S]-reboxetine long term safety study in post-shingles pain [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00354094?term=NCT00354094&rank=1.
   Google Scholar
• Pfizer. A trial assessing the long term safety and tolerability of [S,S]-reboxetine in patients with post-shingles pain [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00353808?term=NCT00353808&rank=1.
   Google Scholar
• Pfizer. [S,S]-reboxetine dose-range finding trial [Internet]; 2006. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00288652?term=NCT00288652&rank=1.
   Google Scholar
• Pfizer. Study of [S,S]-reboxetine in patients with postherpetic neuralgia, who are gabapentin treatment failures [Internet]; 2005. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00143442?term=NCT00143442&rank=1.
   Google Scholar
• Pfizer. Evaluation of a novel methodology in the assessment of urethral function using SS-RBX [Internet]; 2005. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00141128?term=NCT00141128&rank=1.
   Google Scholar
• Pfizer. An 8 week study looking at the efficacy, toleration and safety of SS-RBX for stress urinary incontinence [Internet]; 2005. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00138749?term=NCT00138749&rank=1.
   Google Scholar
• Pfizer. Double-blind, four week trial of [S,S]-reboxetine and atomoxetine in adults with attention deficit hyperactivity disorder [Internet]; 2005. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00562055?term=NCT00562055&rank=1.
   Google Scholar
• Pfizer. A 14-week, multi-center study of [S,S]-reboxetine in patients with fibromyalgia [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00612170?term=NCT00612170&rank=1.
   Google Scholar
• Pfizer. Long-term OL study of [S,S]-RBX in patients with fibromyalgia [Internet]; 2008. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00607256
   Google Scholar
• Datamonitor. Pfizer: novel pipeline streamlined post-Wyeth merger [Internet]; 2009. [cited 2015 Jul 30]. Available from: http://www.datamonitor.com/store/News/pfizer_novel_pipeline_streamlined_post_wyeth_merger?productid=9DF39DA6-BDBD-4BD5-8620-B848D96166E2.
   Google Scholar
• Holaday JW, inventor; Patent WO2012109445 A1 – hybrid opioid compounds and compositions [Internet]; 2012. [cited 2015 Jul 30]. Available from: http://www.google.com/patents/WO2012109445A1?cl=en.
   Google Scholar
• QRxPharma. Extension study to evaluate the safety of Q8003 in patients with acute moderate to severe pain [Internet]; 2007. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00565760?term=Q8003&rank=6.
   Google Scholar
• QRxPharma. Comparison of the efficacy and safety of Q8003 versus its individual components in bunionectomy patients [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00831051?term=Q8003&rank=1.
   Google Scholar
• QRxPharma. Pilot study of the efficacy and safety of Q8003 in patients who have undergone total knee arthroplasty or total hip arthroplasty [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT00818493?term=Q8003&rank=4.
   Google Scholar
• QRxPharma. Comparison of the efficacy and safety of Q8003 versus its individual components in bunionectomy patients [Internet]; 2009. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01016808?term=Q8003&rank=3.
   Google Scholar
• QRxPharma. Double blind efficacy and safety study of flexible-dose vs low-dose Q8003 after undergoing primary unilateral total knee arthroplasty [Internet]; 2010. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01055015?term=Q8003&rank=5.
   Google Scholar
• QRxPharma. Comparison of the safety of Q8003 versus morphine equivalent doses of its components (oxycodone and morphine) in bunionectomy patients [Internet]; 2012. [cited 2015 Jul 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT01280331?term=Q8003&rank=2.
   Google Scholar
• QRxPharma. QRxPharma halts MoxDuo development [Internet]; 2014. [cited 2015 Jul 30]. Available from: http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=10835.
   Google Scholar
• International Association for the study of pain 2014–2015; Epidemiology of neuropathic pain: how common is neuropathic pain, and what is its impact? [Internet]; 2014. [cited 2015 Jul 30]. Available from: http://iasp.files.cms-plus.com/AM/Images/GYAP/Epidemiology%20of%20Neuropathic%20Pain.pdf.
   Google Scholar
• Lauria G, Faber CG, Merkies ISJ, et al. Diagnosis of neuropathic pain: challenges and possibilities. Expert Opin Med Diagn. 2012;6(2):89–93.
   PubMedGoogle Scholar

*This editorial addresses the impact of validated scales tools, psychophysical tests and morphometric analysis of small nerve fibers as well as a molecular substrate for novel gene mutations on the diagnosis of neuropathic pain in clinical practice.

• Teixeira MJ. Challenges in the treatment of neuropathic pain. Drugs Today (Barc). 2009;45(Suppl C):1–5.
   PubMedGoogle Scholar
• Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–251.
   PubMed Web of Science ®Google Scholar

**Evidence based pharmacological management recommendations review based on randomized clinical trial comparing different option line treatments for neuropathic pain in clinical practice.

• Jongen JL, Hans G, Benzon HT, et al. Neuropathic pain and pharmacological treatment. Pain Pract. 2014;14(3):283–295.
   PubMed Web of Science ®Google Scholar
• Hoke A, Simpson DM, Freeman R. Designing innovative therapies for neuropathic pain: preclinical and early clinical development challenges. J Peripher Nerv Syst. 2014;19(supplement):S28–S29.
   PubMed Web of Science ®Google Scholar

*This is a supplement to reference 118, a symposium outlining future directions for neuropathy pain clinical research.

• Hoke A, Simpson DM, Freeman R. Challenges in developing novel therapies for peripheral neuropathies: a summary of The Foundation for Peripheral Neuropathy Scientific Symposium 2012. J Peripher Nerv Syst. 2013;18(1):1–6.
   PubMed Web of Science ®Google Scholar

**This is a summary of keynote speakers remarks at the Foundation for Peripheral Neuropathy scientific meeting between basic and clinical scientists studying peripheral neuropathies and representatives from the drug industry, National Institutes of Health, and Federal Drug Administration.

• Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375(9715):686–695.
   PubMed Web of Science ®Google Scholar
• Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807–819.
   PubMed Web of Science ®Google Scholar

**This is a review of current approaches in assessment and diagnosis of neuropathic pain as well as recent research on its pathophysiologic mechanisms described through randomized controlled clinical trials of different medications.